DETROL

LOE Approaching

tolterodine tartrate

NDAORALTABLET
Approved
Mar 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

CLINICAL PHARMACOLOGY Tolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl…

Clinical Trials (5)

NCT01089751Phase 4Completed

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

Started Mar 2010
322 enrolled
Overactive Bladder
NCT00768521Phase 1Completed

A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)

Started Sep 2008
20 enrolled
Overactive Bladder
NCT00465894N/ACompleted

Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms

Started Apr 2007
58 enrolled
Overactive Bladder
NCT00411437Phase 4Completed

Effects Of Detrol LA On Memory And Cognition In Elderly Population

Started Dec 2006
220 enrolled
MemoryCognition
NCT00230789Phase 4Completed

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

Started Oct 2005
417 enrolled
Urinary Incontinence